Published by Josh White on 25th January 2022
(Sharecast News) - Point-of-care, central laboratory device and chemistry reagent company EKF Diagnostics said on Tuesday that continued strong trading would result in its performance for 2021, including adjusted EBITDA, ahead of already-upgraded market expectations.
URL: http://www.digitallook.com/dl/news/story/32414430/...